Want a Ride with $ACET?There's an interesting fundamental catalyst behind this – it will re-test $1.20 and trade higher!
PD: We duplicated 3 client accounts since Monday.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.2914 USD
−117.12 M USD
0.00 USD
65.38 M
About Adicet Bio, Inc.
Sector
Industry
CEO
Chen Schor
Website
Headquarters
Boston
Founded
2014
FIGI
BBG00JCXSJP3
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
$ACET Adicet Bio Inc Long term PT 21 and higherAdicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facili
ACET Trending UpPublishing this on the Daily scale as well.
Price needs to find support at the .50 and then the .618 fib levels to move up to the target at 1.618 extension .
Appears to be currently in a falling wedge with a $12.50 bottom which is also the .618 level of the recent price action.
Will be a challenge w
ACET Trending UpPrice needs to find support at the .50 and then the .618 fib levels to move up to the target at 1.618 extension.
Appears to be currently in a falling wedge with a $12.50 bottom which is also the .618 level of the recent price action.
Will be a challenge with the current market conditions but technic
Adicet Bio. Down. ACETFirst biopharma that is about to flip in our most recent experience. Just look, this baby can't climb forever.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red
Leg C becomes Leg BHello, it has been a while since I write. With this stock, I wrote Leg B twice. If you read my previous article, you know that there is a Leg B and Leg C, but in this article, I wrote Leg B twice why because Leg C becomes another Leg B unless there is a change in trend.
Thank you for reading!
$ACET entry PT 12.70-13 Long term Target PT 32 and higherGuggenheim Maintains Buy on Adicet Bio, Raises Price Target to $32
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell re
ACET - Long Setup Break above 8.53, Stop signal 7.66. First target 11.37. Insider selling from CEO at 10.53-15.34 throughout the year.
Long play in ACET, entry: 10.55, target: $15.00, stop 9.70On Friday June 18, ACET was once again traded down to the support at $10. It came back strong, however, and closed near the high of the day. There was heavy volume as buyers obviously saw value at this level.
If it continues up this week, preferably under volume, I would be long with targets at the
ACET keep eye on 12USD levelNASDAQ: ACET price target $27.50 (very bullish/strong buy), it has been coming down from July 20USD touched 10USD and consolidating. Will it reach pre-covid level (48-64USD) ...it has long way to go. But if it reaches avoce 21USD it may get there. I will buy when it touches 12USD again. Or goes abov
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where ACET is featured.
Mid-weight oncology stocks: The dark horses of cancer research
18 No. of Symbols
See all sparks
Related stocks
Frequently Asked Questions
The current price of ACET is 0.7057 USD — it has decreased by −9.20% in the past 24 hours. Watch Adicet Bio, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Adicet Bio, Inc. stocks are traded under the ticker ACET.
ACET stock has risen by 8.57% compared to the previous week, the month change is a 21.67% rise, over the last year Adicet Bio, Inc. has showed a −55.34% decrease.
We've gathered analysts' opinions on Adicet Bio, Inc. future price: according to them, ACET price has a max estimate of 8.00 USD and a min estimate of 4.00 USD. Watch ACET chart and read a more detailed Adicet Bio, Inc. stock forecast: see what analysts think of Adicet Bio, Inc. and suggest that you do with its stocks.
ACET reached its all-time high on Feb 26, 2018 with the price of 147.6818 USD, and its all-time low was 0.4471 USD and was reached on Apr 10, 2025. View more price dynamics on ACET chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ACET stock is 14.24% volatile and has beta coefficient of 1.79. Track Adicet Bio, Inc. stock price on the chart and check out the list of the most volatile stocks — is Adicet Bio, Inc. there?
Today Adicet Bio, Inc. has the market capitalization of 64.28 M, it has increased by 36.22% over the last week.
Yes, you can track Adicet Bio, Inc. financials in yearly and quarterly reports right on TradingView.
Adicet Bio, Inc. is going to release the next earnings report on Aug 6, 2025. Keep track of upcoming events with our Earnings Calendar.
ACET earnings for the last quarter are −0.31 USD per share, whereas the estimation was −0.33 USD resulting in a 6.53% surprise. The estimated earnings for the next quarter are −0.31 USD per share. See more details about Adicet Bio, Inc. earnings.
Adicet Bio, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ACET net income for the last quarter is −28.21 M USD, while the quarter before that showed −28.73 M USD of net income which accounts for 1.79% change. Track more Adicet Bio, Inc. financial stats to get the full picture.
No, ACET doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 20, 2025, the company has 152 employees. See our rating of the largest employees — is Adicet Bio, Inc. on this list?
Like other stocks, ACET shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Adicet Bio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Adicet Bio, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Adicet Bio, Inc. stock shows the sell signal. See more of Adicet Bio, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.